Endurant Capital Management LP Buys Vocera Communications Inc, Bristol-Myers Squibb Company, Gilead Sciences Inc, Sells Allergan PLC, Celgene Corp, CVS Health Corp

San Mateo, CA, based Investment company Endurant Capital Management LP buys Vocera Communications Inc, Bristol-Myers Squibb Company, Gilead Sciences Inc, Takeda Pharmaceutical Co, Icon PLC, HCA Healthcare Inc, IntriCon Corp, AtriCure Inc, Laboratory Corp of America Holdings, AmerisourceBergen Corp, Evolent Health Inc, LivaNova PLC, Tenet Healthcare Corp, Aclaris Therapeutics Inc, Centene Corp, Thermo Fisher Scientific Inc, Luminex Corp, Neon Therapeutics Inc, Anthem Inc, iRhythm Technologies Inc, Liquidia Technologies Inc, Vericel Corp, Intersect ENT Inc, Axovant Gene Therapies, Abbott Laboratories, Ocular Therapeutix Inc, Align Technology Inc, Marinus Pharmaceuticals Inc, AbbVie Inc, Krystal Biotech Inc, Tivity Health Inc, Viking Therapeutics Inc, Agilent Technologies Inc, Molina Healthcare Inc, Sientra Inc, Teladoc Health Inc, ViewRay Inc, PTC Therapeutics Inc, Henry Schein Inc, Haemonetics Corp, Immunogen Inc, VistaGen Therapeutics Inc, Surgery Partners Inc, Biohaven Pharmaceutical Holding Co, Dynavax Technologies Corp, Gritstone Oncology Inc, Osmotica Pharmaceuticals PLC, sells Allergan PLC, Celgene Corp, CVS Health Corp, Shire PLC, DaVita Inc, Allscripts Healthcare Solutions Inc, Hologic Inc, Encompass Health Corp, Medtronic PLC, Zimmer Biomet Holdings Inc, Oxford Immunotec Global PLC, UnitedHealth Group Inc, Sanofi SA, Dentsply Sirona Inc, Insulet Corp, Iovance Biotherapeutics Inc, Nevro Corp, Mylan NV, Fluidigm Corp, PetMed Express Inc, Accuray Inc, Array BioPharma Inc, Stryker Corp, Teva Pharmaceutical Industries, Bausch Health Inc, Boston Scientific Corp, Johnson & Johnson, Axogen Inc, Sarepta Therapeutics Inc, Amicus Therapeutics Inc, McKesson Corp, Axsome Therapeutics Inc, AnaptysBio Inc, Aldeyra Therapeutics Inc during the 3-months ended 2019Q1, according to the most recent filings of the investment company, Endurant Capital Management LP. As of 2019Q1, Endurant Capital Management LP owns 67 stocks with a total value of $238 million. These are the details of the buys and sells.

• New Purchases: VCRA, GILD, TAK, HCA, ATRC, LH, EVH, LIVN, THC, ACRS, CNC, TMO, LMNX, NTGN, ANTM, VCEL, XENT, AXGT, ABT, ALGN, MRNS, ABBV, TVTY, A, MOH, SIEN, TDOC, VRAY, PTCT, HSIC, HAE, IMGN, VTGN, SGRY, BHVN, DVAX, GRTS,
• Added Positions: BMY, ICLR, IIN, ABC, IRTC, LQDA, OCUL, KRYS, VKTX, OSMT,
• Reduced Positions: AGN, CVS, MDT, ZBH, OXFD, XRAY, ARRY, RCM, BHC, WMGI, SRPT, CI, AXSM, ANAB, ALDX,
• Sold Out: CELG, SHPG, DVA, MDRX, HOLX, EHC, UNH, SNY, PODD, IOVA, NVRO, MYL, FLDM, PETS, ARAY, SYK, TEVA, BSX, JNJ, AXGN, FOLD, MCK,

For the details of Endurant Capital Management LP's stock buys and sells, go to https://www.gurufocus.com/guru/endurant+capital+management+lp/current-portfolio/portfolio

These are the top 5 holdings of Endurant Capital Management LP

1. Bristol-Myers Squibb Company (BMY) - 291,281 shares, 5.83% of the total portfolio. Shares added by 490.39%
2. IntriCon Corp (IIN) - 552,457 shares, 5.82% of the total portfolio. Shares added by 122.78%
3. Icon PLC (ICLR) - 100,874 shares, 5.78% of the total portfolio. Shares added by 145.24%
4. Vocera Communications Inc (VCRA) - 390,887 shares, 5.19% of the total portfolio. New Position
5. Cigna Corp (CI) - 66,997 shares, 4.52% of the total portfolio. Shares reduced by 5.56%

New Purchase: Vocera Communications Inc (VCRA)

Endurant Capital Management LP initiated holding in Vocera Communications Inc. The purchase prices were between $29.89 and $41.68, with an estimated average price of $35.49. The stock is now traded at around $33.90. The impact to a portfolio due to this purchase was 5.19%. The holding were 390,887 shares as of .

New Purchase: Gilead Sciences Inc (GILD)

Endurant Capital Management LP initiated holding in Gilead Sciences Inc. The purchase prices were between $62.53 and $70.05, with an estimated average price of $66.46. The stock is now traded at around $65.30. The impact to a portfolio due to this purchase was 4.25%. The holding were 155,793 shares as of .

New Purchase: Takeda Pharmaceutical Co Ltd (TAK)

Endurant Capital Management LP initiated holding in Takeda Pharmaceutical Co Ltd. The purchase prices were between $16.7 and $21.52, with an estimated average price of $20.07. The stock is now traded at around $18.03. The impact to a portfolio due to this purchase was 3.74%. The holding were 437,436 shares as of .

New Purchase: HCA Healthcare Inc (HCA)

Endurant Capital Management LP initiated holding in HCA Healthcare Inc. The purchase prices were between $119.44 and $144.26, with an estimated average price of $134.31. The stock is now traded at around $123.18. The impact to a portfolio due to this purchase was 3.29%. The holding were 60,075 shares as of .

New Purchase: AtriCure Inc (ATRC)

Endurant Capital Management LP initiated holding in AtriCure Inc. The purchase prices were between $26.38 and $33.34, with an estimated average price of $30.44. The stock is now traded at around $29.41. The impact to a portfolio due to this purchase was 3%. The holding were 266,577 shares as of .

New Purchase: Laboratory Corp of America Holdings (LH)

Endurant Capital Management LP initiated holding in Laboratory Corp of America Holdings. The purchase prices were between $123.7 and $156.3, with an estimated average price of $143.14. The stock is now traded at around $165.36. The impact to a portfolio due to this purchase was 2.88%. The holding were 44,869 shares as of .

Added: Bristol-Myers Squibb Company (BMY)

Endurant Capital Management LP added to a holding in Bristol-Myers Squibb Company by 490.39%. The purchase prices were between $45.12 and $53.8, with an estimated average price of $49.88. The stock is now traded at around $46.63. The impact to a portfolio due to this purchase was 4.84%. The holding were 291,281 shares as of .

Added: Icon PLC (ICLR)

Endurant Capital Management LP added to a holding in Icon PLC by 145.24%. The purchase prices were between $121.3 and $146.95, with an estimated average price of $136.28. The stock is now traded at around $138.56. The impact to a portfolio due to this purchase was 3.42%. The holding were 100,874 shares as of .

Added: IntriCon Corp (IIN)

Endurant Capital Management LP added to a holding in IntriCon Corp by 122.78%. The purchase prices were between $21.54 and $29.43, with an estimated average price of $25.48. The stock is now traded at around $25.51. The impact to a portfolio due to this purchase was 3.21%. The holding were 552,457 shares as of .

Added: AmerisourceBergen Corp (ABC)

Endurant Capital Management LP added to a holding in AmerisourceBergen Corp by 961.58%. The purchase prices were between $73.37 and $86.85, with an estimated average price of $80.35. The stock is now traded at around $77.86. The impact to a portfolio due to this purchase was 2.67%. The holding were 88,536 shares as of .

Added: iRhythm Technologies Inc (IRTC)

Endurant Capital Management LP added to a holding in iRhythm Technologies Inc by 179.35%. The purchase prices were between $65.44 and $97.34, with an estimated average price of $85.3. The stock is now traded at around $70.79. The impact to a portfolio due to this purchase was 1.01%. The holding were 50,333 shares as of .

Added: Liquidia Technologies Inc (LQDA)

Endurant Capital Management LP added to a holding in Liquidia Technologies Inc by 501.26%. The purchase prices were between $10.82 and $21.79, with an estimated average price of $16.07. The stock is now traded at around $9.87. The impact to a portfolio due to this purchase was 0.93%. The holding were 235,329 shares as of .

Sold Out: Celgene Corp (CELG)

Endurant Capital Management LP sold out a holding in Celgene Corp. The sale prices were between $64.09 and $94.34, with an estimated average price of $87.12.

Sold Out: Shire PLC (SHPG)

Endurant Capital Management LP sold out a holding in Shire PLC. The sale prices were between $172.15 and $179.2, with an estimated average price of $176.08.

Sold Out: DaVita Inc (DVA)

Endurant Capital Management LP sold out a holding in DaVita Inc. The sale prices were between $49.95 and $59.21, with an estimated average price of $55.37.

Sold Out: Allscripts Healthcare Solutions Inc (MDRX)

Endurant Capital Management LP sold out a holding in Allscripts Healthcare Solutions Inc. The sale prices were between $9.54 and $12.21, with an estimated average price of $11.06.

Sold Out: Hologic Inc (HOLX)

Endurant Capital Management LP sold out a holding in Hologic Inc. The sale prices were between $38.28 and $48.4, with an estimated average price of $45.03.

Sold Out: Encompass Health Corp (EHC)

Endurant Capital Management LP sold out a holding in Encompass Health Corp. The sale prices were between $58.4 and $68.4, with an estimated average price of $63.75.

Here is the complete portfolio of Endurant Capital Management LP. Also check out:

1. Endurant Capital Management LP's Undervalued Stocks
2. Endurant Capital Management LP's Top Growth Companies, and
3. Endurant Capital Management LP's High Yield stocks
4. Stocks that Endurant Capital Management LP keeps buying